Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma - Quiz - MDSpire

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • By

  • Mahir Hasan

  • Wolfram Samlowski

  • Samer Nakhle

  • May 8, 2026

  • 0 min

Share

Original Source(s)

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • by Mahir Hasan, Wolfram Samlowski, Samer Nakhle

  • May 8, 2026

Related Content

Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy

Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential